Decision Analysis to Address Clinical Dilemmas in Resource-Limited Settings: Aspirin for Stroke of Undetermined Etiology as a Case Study

Aaron Berkowitz, MD, PhD

Professor and Director of Global Health, Kaiser Permanente Bernard J. Tyson School of Medicine
Senior Specialist Consultant in Neurology, Médecins Sans Frontières
Health and Policy Advisor in Neurology, Partners In Health
Case

A 69-year-old woman with a history of hypertension presents to a health center in rural Haiti two days after sudden development of right-sided paralysis and difficulty speaking.

A diagnosis of stroke is made. No CT scan is available to determine if the stroke is ischemic or hemorrhagic.

In addition to acute stabilization, evaluation for etiology, risk factor modification, and rehabilitation, would you initiate aspirin for long-term secondary stroke prevention?
Survey

For this patient with stroke and no CT available to determine if the stroke is ischemic or hemorrhagic, would you administer aspirin for long-term secondary stroke prevention?

A. Yes, I would treat the patient with aspirin
B. No, I would not treat the patient with aspirin
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

Salim Yusuf, Shofiqul Islam, Clara K Chow, Sumathy Rangarajan, Gilles Dagenais, Rafael Diaz, Rajeev Gupta, Roya Kelishadi, Romaina Iqbal, Alvaro Avezum, Annamarie Kruger, Raman Kutty, Fernando Lanas, Liu Lisheng, Li Wei, Patricio Lopez-Jaramillo, Aytekin Oguz, Omar Rahman, Hany Swidan, Khalid Yusoff, Witold Zatonski, Annika Rosengren, Koon K Teo, on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators

<table>
<thead>
<tr>
<th>Drug Type</th>
<th>Overall</th>
<th>High-income countries</th>
<th>Upper middle-income countries</th>
<th>Lower middle-income countries</th>
<th>Low-income countries</th>
<th>( P_{\text{trend}} )</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stroke</strong></td>
<td>2292</td>
<td>213</td>
<td>691</td>
<td>1042</td>
<td>346</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Antiplatelet drugs</strong></td>
<td>557 (24.3%)</td>
<td>113 (53.1%)</td>
<td>137 (19.8%)</td>
<td>294 (28.2%)</td>
<td>13 (3.8%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>β blockers</strong></td>
<td>215 (9.4%)</td>
<td>44 (20.7%)</td>
<td>87 (12.6%)</td>
<td>62 (6.0%)</td>
<td>22 (6.4%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>ACE inhibitors or ARBs</strong></td>
<td>426 (18.6%)</td>
<td>89 (41.8%)</td>
<td>195 (28.2%)</td>
<td>135 (13.0%)</td>
<td>7 (2.0%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Diuretics</strong></td>
<td>348 (15.2%)</td>
<td>48 (22.5%)</td>
<td>109 (15.8%)</td>
<td>180 (17.3%)</td>
<td>11 (3.2%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Calcium-channel blockers†</strong></td>
<td>331 (14.4%)</td>
<td>37 (17.4%)</td>
<td>80 (11.6%)</td>
<td>202 (19.4%)</td>
<td>12 (3.5%)</td>
<td>0.0307</td>
</tr>
<tr>
<td><strong>Blood-pressure-lowering drugs‡</strong></td>
<td>916 (40.0%)</td>
<td>129 (60.6%)</td>
<td>293 (42.4%)</td>
<td>449 (43.1%)</td>
<td>45 (13.0%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Statins</strong></td>
<td>206 (9.0%)</td>
<td>110 (51.6%)</td>
<td>72 (10.4%)</td>
<td>22 (2.1%)</td>
<td>2 (0.6%)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

_Lancet 2011; 378: 1231–43_
Global Access to CT

Global atlas of medical devices

WHO medical devices technical series
Global Access to CT

- High-income countries: **42** CT scanners per 1 million population

- Low-income countries: **0.32** CT scanners per 1 million population
AHA/ASA Guideline

Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2013 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke
A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

AHA/ASA Guideline

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings
A decision analysis

Aaron L. Berkowitz, M. Brandon Westover, Matt T. Bianchi, Sherry H-Y. Chou
Decision analysis

• Decision Tree
  • Inputs
  • Base case
  • Sensitivity analysis
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings
Decision analysis

• Decision Tree
• Inputs
• Base case
• Sensitivity analysis
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings

<table>
<thead>
<tr>
<th></th>
<th>Without aspirin, %</th>
<th>With aspirin, %</th>
<th>RR with aspirin</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yearly rate of IS after IS(^\text{15})</td>
<td>4.53</td>
<td>3.58</td>
<td>0.78</td>
<td>0.68-0.91</td>
</tr>
<tr>
<td>Yearly rate of ICH after IS(^\text{15})</td>
<td>0.14</td>
<td>0.32</td>
<td>1.90</td>
<td>1.06-3.44</td>
</tr>
<tr>
<td>Yearly rate of IS after ICH(^\text{13})</td>
<td>2.31</td>
<td>0.51</td>
<td>0.23</td>
<td>0.03-1.68</td>
</tr>
<tr>
<td>Yearly rate of ICH after ICH(^\text{14})</td>
<td>1.34</td>
<td>2.54</td>
<td>1.74</td>
<td>1.00-3.04</td>
</tr>
<tr>
<td>Acute mortality rate after IS(^\text{16})</td>
<td>9.44</td>
<td>4.90</td>
<td>0.53</td>
<td>0.30-0.95</td>
</tr>
<tr>
<td>Acute mortality rate after ICH(^\text{17})</td>
<td>26.71</td>
<td>37.67</td>
<td>1.41</td>
<td>1.21-1.64</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes after IS,(^\text{18}) %</td>
<td>44</td>
<td>28</td>
<td>28</td>
</tr>
<tr>
<td>Outcomes after ICH,(^\text{19}) %</td>
<td>31</td>
<td>40</td>
<td>29</td>
</tr>
<tr>
<td>Quality of life(^\text{22})</td>
<td>0.76</td>
<td>0.39</td>
<td>0.11</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval; ICH = intracerebral hemorrhage; IS = ischemic stroke; RR = relative risk.
Decision analysis

• Decision Tree
• Inputs
• Base case analysis
• Sensitivity analysis
Decision analysis

- Decision Tree
- Markov state transition model
- Inputs
- Base case analysis
  - 69-year-old (average age at stroke onset in LMIC)
  - 34% of acute strokes due to ICH
- Sensitivity analysis
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study

<table>
<thead>
<tr>
<th></th>
<th>All (n=3000)</th>
<th>High-income countries* (n=422)</th>
<th>South America† (n=151)</th>
<th>Southeast Asia‡ (n=1146)</th>
<th>India (n=958)</th>
<th>Africa§ (n=323)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61.1 (12.7)</td>
<td>66.0 (13.3)</td>
<td>65.6 (13.4)</td>
<td>58.5 (11.6)</td>
<td>58.9 (12.0)</td>
<td>57.7 (15.3)</td>
</tr>
<tr>
<td>Age ≤45 years</td>
<td>415 (14%)</td>
<td>32 (8%)</td>
<td>13 (9%)</td>
<td>146 (13%)</td>
<td>147 (15%)</td>
<td>77 (24%)</td>
</tr>
<tr>
<td>Women</td>
<td>1106 (37%)</td>
<td>169 (40%)</td>
<td>71 (47%)</td>
<td>412 (36%)</td>
<td>313 (33%)</td>
<td>141 (44%)</td>
</tr>
<tr>
<td>Intracerebral haemorrhagic stroke</td>
<td>663 (22%)</td>
<td>40 (9%)</td>
<td>39 (26%)</td>
<td>257 (22%)</td>
<td>218 (23%)</td>
<td>109 (34%)</td>
</tr>
<tr>
<td>Ischaemic stroke</td>
<td>2337 (78%)</td>
<td>382 (91%)</td>
<td>112 (74%)</td>
<td>889 (78%)</td>
<td>740 (77%)</td>
<td>214 (66%)</td>
</tr>
</tbody>
</table>

Data are mean (SD) or number (%). OCSP=Oxfordshire Community Stroke Project. ECG=electrocardiogram. *Australia, Canada, Croatia, Denmark, Germany, Iran, and Poland. †Argentina, Brazil, Chile, Colombia, Ecuador, and Peru. ‡China, Malaysia, and Philippines. §Mozambique, Nigeria, South Africa, Sudan, and Uganda. ¶Percentages are proportions of the number of cases with ischaemic stroke.

**Table 1: Demographic and clinical characteristics of cases**
Based on estimated ~12 million strokes in LMIC per year, aspirin administration to all patients with stroke would be predicted to lead to:

- estimated yearly decrease of ~85,000 recurrent strokes
- estimated yearly decrease of ~4,000 stroke-related mortalities

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>No treatment with aspirin</th>
<th>Treatment with aspirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (per 1,000 patients per year)</td>
<td>103.32</td>
<td>102.97</td>
</tr>
<tr>
<td>Ischemic strokes (per 1,000 patients per year)</td>
<td>33.32</td>
<td>22.26</td>
</tr>
<tr>
<td>Intracerebral hemorrhages (per 1,000 patients per year)</td>
<td>4.78</td>
<td>8.55</td>
</tr>
</tbody>
</table>
Decision analysis

- Decision Tree
- Inputs
- Base case analysis
- Sensitivity analysis
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

**RESTART Collaboration***

**Interpretation** These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention.

![Graph showing Kaplan-Meier plot of first occurrence of recurrent symptomatic intracerebral haemorrhage](image)

*Figure 2: Kaplan-Meier plot of the first occurrence of recurrent symptomatic intracerebral haemorrhage*

Numbers at risk refer to survivors under follow-up at the start of each year according to treatment allocation. Cumulative events indicate the participants in follow-up with a first event. HR=hazard ratio.
Stroke

COMMENTS AND OPINIONS

Inpatient Management of Acute Stroke of Unknown Type in Resource-Limited Settings

Morgan L. Prust, MD; Deanna Saylor, MD, MHS; Stanley Zimba, MBChB, MMED; Fred Stephen Sarfo, MD, PhD; Gentle S. Shrestha, MD; Aaron Berkowitz, MD, PhD*; Nirali Vora, MD*

ABSTRACT: Stroke is the second leading cause of death and disability worldwide, with a disproportionate burden on low-and middle-income countries. Critical elements of guideline-based stroke care developed in high-income countries are not applicable to resource-limited settings, where lack of access to neuroimaging prevents clinicians from distinguishing between ischemic stroke and intracranial hemorrhage, requiring challenging clinical decision-making, particularly in the acute setting. We discuss strategies for acute inpatient management of stroke of unknown type with a focus on blood pressure management and antiplatelet therapy when neuroimaging is unavailable, and review some of the challenges and strategies for successfully implementing stroke unit care in resource-limited health care settings.

Key Words: blood pressure • cause of death • clinical decision-making • inpatient • neuroimaging
Discussion

What clinical dilemma(s) have you encountered for which a decision analysis model may be useful?

Consider:
- Clinical trials unlikely to ever be performed
- Clinical questions for which there is available data on which to base the model